Loading...

Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer

Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines
Main Authors: Rana, Zohaib, Diermeier, Sarah, Hanif, Muhammad, Rosengren, Rhonda J.
Format: Artigo
Language:Inglês
Published: MDPI 2020
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7168248/
https://ncbi.nlm.nih.gov/pubmed/32019149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8020022
Tags: Add Tag
No Tags, Be the first to tag this record!